Traws Pharma, Inc.
TRAWNasdaq
$0.67
↑ +1.1%Jul 17 close · end-of-day
Price
1Y↓ -57.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.1M
Enterprise Value
$7.1M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$19.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
365.8%
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
-58.6%
Company profile
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
- CEO
- Steven M. Fruchtman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 17
- Headquarters
- Pennsylvania
- Website
- www.trawspharma.com
Management & directors
- Dukes Iain D.Chief Executive Officer
- Parker Charles NolanChief Financial Officer
- Pauza Charles DavidChief Science Officer Virology
- Redfield RobertChief Medical Officer
- Savchuk NikolayChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
TRAW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.53↓ -125.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $231,000.00 | $226,000.00 | $226,000.00 | $226,000.00 | $226,000.00 | $2.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$25.0M | -$16.5M | -$19.6M | -$20.3M | -$142.4M | -$17.9M |
| Net income | -$25.2M | -$16.2M | -$19.0M | -$18.9M | -$166.5M | $9.2M |
| Diluted EPS | -$2.17 | -$0.96 | -$0.91 | -$22.57 | -$35.21 | $0.82 |
| Operating cash flow | -$23.1M | -$19.5M | -$16.3M | -$17.9M | -$29.8M | -$18.2M |
| Free cash flow | -$23.1M | — | — | -$17.9M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -10819.5% | -7299.1% | -8684.5% | -8981.4% | -62997.3% | -640.7% |
| Net margin | -10890.5% | -7151.8% | -8391.2% | -8384.1% | -73682.7% | 328.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $57,000.00 | $57,000.00 | $56,000.00 | $57,000.00 | $2.7M | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$123.3M | -$8.5M | -$5.3M | -$5.2M | -$1.2M | -$4.1M | -$7.4M | -$6.9M |
| Net income | -$123.1M | -$8.5M | -$29.9M | $21.5M | -$915,000.00 | -$4.0M | -$7.4M | -$7.1M |
| Diluted EPS | -$20.52 | -$1.49 | -$7.28 | $2.09 | -$0.11 | -$0.34 | -$0.82 | -$0.53 |
| Operating cash flow | -$9.9M | -$11.5M | -$4.0M | -$5.4M | -$6.0M | -$4.0M | -$2.8M | -$2.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -216400.0% | -14975.4% | -9425.0% | -9128.1% | -45.7% | — | — | — |
| Net margin | -216040.4% | -14868.4% | -53432.1% | 37701.8% | -33.5% | — | — | — |
Company news
Jun 22, 2026
Jun 18, 2026
Jun 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-16 | ORBIMED ADVISORS LLC | Buy | 597,729 | $1.67 | $998,207.43 | filing |
| 2025-12-12 | Parker Charles Nolan· Chief Financial Officer | Award | 15,393 | $0.00 | $0.00 | filing |
| 2025-12-12 | Leaman John Harold | Award | 4,058 | $0.00 | $0.00 | filing |
| 2025-12-12 | Clarke Trafford | Award | 6,157 | $0.00 | $0.00 | filing |
| 2025-12-12 | CAUTREELS WERNER | Award | 4,874 | $0.00 | $0.00 | filing |
| 2025-12-12 | Shoemaker Mary Teresa | Award | 6,157 | $0.00 | $0.00 | filing |
| 2025-12-12 | STOVER JACK E | Award | 6,157 | $0.00 | $0.00 | filing |
| 2025-12-12 | Dukes Iain D.· Chief Executive Officer | Award | 36,943 | $0.00 | $0.00 | filing |
| 2025-12-12 | Pauza Charles David· Chief Science Officer Virology | Award | 18,471 | $0.00 | $0.00 | filing |
| 2025-12-12 | Redfield Robert· Chief Medical Officer | Award | 16,419 | $0.00 | $0.00 | filing |
| 2025-12-12 | Savchuk Nikolay· Chief Operating Officer | Award | 16,419 | $0.00 | $0.00 | filing |
Latest 11 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.